Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

about

Breast cancer in 2017: Spurring science, marking progress, and influencing history.Description of Genetic Variants in Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine

P2860

Q49907753-78C9904D-0BCE-48B6-9AF2-508E7AA7EE1F Q58795187-DECFC068-1AF2-42C2-9B2F-70B9F6972D33

P2860

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Item

http://www.wikidata.org/entity/Q41470948

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Baseline clinical predictors o ...... with advanced ovarian cancer.

@en

type

Item

label

Baseline clinical predictors o ...... with advanced ovarian cancer.

@en

prefLabel

Baseline clinical predictors o ...... with advanced ovarian cancer.

@en

P1476

Baseline clinical predictors o ...... with advanced ovarian cancer.

@en

P2093

Amit M Oza

http://www.w3.org/2001/XMLSchema#string

Charlie Gourley

http://www.w3.org/2001/XMLSchema#string

Jacques De Greve

http://www.w3.org/2001/XMLSchema#string

Joo Ern Ang

http://www.w3.org/2001/XMLSchema#string

L Rhoda Molife

http://www.w3.org/2001/XMLSchema#string

Lee-May Chen

http://www.w3.org/2001/XMLSchema#string

Martin E Gore

http://www.w3.org/2001/XMLSchema#string

Michael Friedlander

http://www.w3.org/2001/XMLSchema#string

Rajiv Kumar

http://www.w3.org/2001/XMLSchema#string

Ronnie Shapira-Frommer

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer

P304

47154-47160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17005

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elena Geuna

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28454085

http://www.w3.org/2001/XMLSchema#string

P932

5564551

http://www.w3.org/2001/XMLSchema#string

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

about

P2860

P2860

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932